期刊
EXPERIMENTAL NEUROLOGY
卷 202, 期 1, 页码 93-99出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2006.05.017
关键词
Parkinson's disease; MPTP; Wallerian degeneration; neurodegeneration
资金
- NIGMS NIH HHS [T32 GM07200] Funding Source: Medline
- NIMH NIH HHS [MH45330] Funding Source: Medline
- NINDS NIH HHS [NS39084] Funding Source: Medline
The progressive loss of the nigrostriatal pathway is a distinguishing feature of Parkinson's disease. Because terminal field loss appears to precede cell body loss, we tested whether the mouse mutant Wld(S), which delays axonal degeneration in a variety of disorders, would ameliorate nigrostriatal degeneration following treatment with the Parkinsonian mimetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The present findings show that the Wld(S) gene product enhances survival, prevents nigrostriatal axon degeneration, and attenuates neurotransmitter loss but does not rescue cell bodies. As MPTP is thought to impair mitochondrial energy production, these data suggest that disease pathology due to metabolic dysfunction could be improved by the Wld(S) gene product. These results suggest new therapeutic avenues for Parkinson's disease. (c) 2006 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据